<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The most relevant clinical trials, assessing the role of glycemic control in reducing cardiovascular risk, are examined </plain></SENT>
<SENT sid="1" pm="."><plain>The UKPDS was the first to address this issue </plain></SENT>
<SENT sid="2" pm="."><plain>More recent trials (ACCORD, ADVANCE and VADT) are controversial and evidences did not support that strict glycemic control (reflected by <z:mpath ids='MPATH_458'>normal</z:mpath> glycated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>) exclusively is sufficient to reduce cardiovascular risk in complicated individuals with long-term type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Some possible reasons for controversies are included </plain></SENT>
</text></document>